LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it began the first in-human trial of Foralumab, a treatment for autoimmune diseases.
The biotechnology company said the product will be tested in healthy volunteers through nasal administration.
The choice of administering the product via intranasal delivery is a "first and major milestone towards the company's objective to develop innovative therapies with alternative routes of administration whilst maximizing efficacy", Tiziana explained.
The phase 1 trial aims to evaluate the safety and tolerability of Foralumab.
"The clinical protocol also includes evaluation of unique biomarkers of immunomodulation, induction of T regulatory cells and anti-inflammation to assess therapeutic potential of the treatment," Tiziana explained.
Tiziana shares were trading down 4.8% around midday on Wednesday at 74.50 pence each.
